OncoGenex Announces Completion of Patient Enrollment in the Borealis-1™ Trial of OGX-427 in Metastatic Bladder Cancer

OncoGenex Announces Completion of Patient Enrollment in the Borealis-1™ Trial
                   of OGX-427 in Metastatic Bladder Cancer

First of Six ORCA™ Trials to Reach Key Phase 2 Enrollment Milestone

PR Newswire

BOTHELL, Wash. and VANCOUVER, British Columbia, July 16, 2013

BOTHELL, Wash. and VANCOUVER, British Columbia, July 16, 2013 /PRNewswire/
--OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced that
enrollment has been completed in Borealis-1™, a company-sponsored, randomized,
placebo-controlled Phase 2 trial of OGX-427 in combination with first-line
gemcitabine and cisplatin in patients with metastatic bladder cancer.

Approximately 180 patients have been randomized into Borealis-1 at 55 clinical
sites throughout North America and Europe. The three-arm trial randomized
patients to receive gemcitabine, cisplatin, and OGX-427 at two dose-levels
(600 mg or 1000 mg) vs. gemcitabine, cisplatin, and placebo. The primary
endpoint of the trial is overall survival. Additional analyses will be
conducted to evaluate benefit/risk of the two dosing levels using clinical
benefit, safety and tolerability outcomes for each dose level.

"There are limited treatment options available for patients with metastatic
bladder cancer and completion of enrollment in Borealis-1 brings us closer to
validating novel therapies, such as OGX-427, that might overcome treatment
resistance and extend survival," stated Cindy Jacobs MD, PhD, Executive Vice
President and Chief Medical Officer of OncoGenex. "We expect data results to
be available in the second-half of 2014, and if the trial is positive, we will
initiate discussion with the Food and Drug Administration regarding next

Borealis-1 is one of two ongoing clinical trials of OGX-427 in metastatic
bladder cancer. The Borealis-2™ trial is an investigator-sponsored, randomized
Phase 2 trial evaluating OGX-427 in combination with docetaxel in patients
with advanced or metastatic bladder cancer who have disease progression
following first-line platinum-based chemotherapy. This trial is sponsored by
the Hoosier Oncology Group and currently enrolling patients. Please visit
http://clinicaltrials.gov/show/NCT01780545 for more information.

Worldwide, nearly 400,000 cases of bladder cancer are diagnosed each year,
with 30 percent of patients having locally invasive or metastatic disease at
the time of diagnosis. Of patients with locally invasive disease, 50 percent
will relapse with metastases within two years. Limited options exist for both
the first- and second-line treatment of advanced bladder cancer, and the
median overall survival times in these settings are approximately 12 to 15
months and 6 months, respectively. Given these short survival times and the
fact that bladder cancer patients frequently develop resistance to
chemotherapy, there continues to be a high unmet need for additional
therapeutic options for this patient population.

OGX-427 is a once-weekly intravenous (IV) experimental drug that is designed
to inhibit production of heat shock protein 27 (Hsp27) to disable cancer
cells' defenses and overcome treatment resistance. Hsp27 is an intracellular
protein that protects cancer cells by helping them survive, leading to
resistance and more aggressive cancer phenotypes. Both the potential
single-agent activity and synergistic activity of OGX-427 with cancer
treatments may increase the overall benefit of existing therapies and augment
the durability of treatment outcomes, which could lead to increased patient

The ORCA (Ongoing Studies Evaluating Treatment Resistance in CAncer) program
encompasses clinical trials of OGX-427. The ORCA program has recently expanded
to encompass six Phase 2 trials in bladder, lung, pancreatic and prostate
cancers. For more information on OGX-427 and ORCA, please visit
www.OncoGenex.com or www.orcatrials.com.

OncoGenex is a biopharmaceutical company committed to the development and
commercialization of new therapies that address treatment resistance in cancer
patients. OncoGenex has a diverse oncology pipeline, with each product
candidate having a distinct mechanism of action and representing a unique
opportunity for cancer drug development.OncoGenexandTeva Pharmaceutical
Industries Ltd. have entered a global collaboration and license agreement to
develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen
is currently in Phase 3 clinical development as a treatment in men with
metastatic castrate-resistant prostate cancer and in patients with advanced,
unresectable non-small cell lung cancer. OGX-427 is in Phase 2 clinical
development and OGX-225 is currently in pre-clinical development. More
information is available at www.OncoGenex.com.

OncoGenex' Forward Looking Statements
This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995, including, but not limited to, statements concerning our anticipated
product development activities, such as expected clinical trial completion and
design and statements regarding the potential benefits and potential
development of our product candidates. All statements other than statements of
historical fact are statements that could be deemed forward-looking
statements. These statements are based on management's current expectations
and beliefs and are subject to a number of risks, uncertainties and
assumptions that could cause actual results to differ materially from those
described in the forward-looking statements, including, among others, the risk
that our product candidates will not demonstrate the hypothesized or expected
benefits, the risk of delays in our expected clinical trials, the risk that
new developments in the rapidly evolving cancer therapy landscape require
changes in our clinical trial plans or limit the potential benefits of our
product candidates and the other factors described in our risk factors set
forth in our filings with theSecurities and Exchange Commissionfrom time to
time, including the Company's Annual Report on Form 10-K and Quarterly Reports
on Form 10-Q. The Company undertakes no obligation to update the
forward-looking statements contained herein or to reflect events or
circumstances occurring after the date hereof, other than as may be required
by applicable law.

Borealis-1™, Borealis-2™ and ORCA™ are registered trademarks of OncoGenex
Pharmaceuticals, Inc.

SOURCE OncoGenex Pharmaceuticals, Inc.

Website: http://www.oncogenex.com
Contact: Media Contact: Jaime Welch, jwelch@oncogenex.com, 604-630-5403;
Investor Relations Contact: Susan Specht, sspecht@oncogenex.com, 425-686-1535
Press spacebar to pause and continue. Press esc to stop.